Current status of gadolinium toxicity in patients with kidney disease

Clinical Journal of the American Society of Nephrology

Volumn 4, Issue 2, 2009, Pages 461-469

  Perazella, Mark A ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOBENATE DIMEGLUMINE; GADOBUTROL; GADODIAMIDE; GADOLINIUM; GADOLINIUM PENTETATE; GADOTERATE MEGLUMINE; GADOTERIDOL; GADOVERSETAMIDE; IODINATED CONTRAST MEDIUM; IOHEXOL; CONTRAST MEDIUM;

CLINICAL TRIAL; CONTRAST INDUCED NEPHROPATHY; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; HUMAN; KIDNEY DISEASE; KIDNEY INJURY; NEPHROGENIC SYSTEMIC FIBROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; RISK FACTOR; SHORT SURVEY; TOXICITY TESTING; TOXICOKINETICS; ANIMAL; CHEMICALLY INDUCED DISORDER; EVIDENCE BASED MEDICINE; REVIEW; RISK ASSESSMENT;

ANIMALS; CONTRAST MEDIA; DOSE-RESPONSE RELATIONSHIP, DRUG; EVIDENCE-BASED MEDICINE; GADOLINIUM; HUMANS; KIDNEY DISEASES; MAGNETIC RESONANCE IMAGING; NEPHROGENIC FIBROSING DERMOPATHY; RISK ASSESSMENT; RISK FACTORS;

EID: 66849141052     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.06011108     Document Type: Short Survey

References (47)

1. Perazella MA, Rodby RA: Gadolinium use in patients with kidney disease: A cause for concern. Semin Dial 20: 179-184, 2007
2. Grobner T: Gadolinium-a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 21: 1104-1108, 2006
3. Marckmann P, Skov L, Rossen, Dupont A, Damholt MB, Heaf JG, Thomsen HS: Nephrogenic systemic fibrosis: Suspected etiological role of gadodiamide used for contrast-enhanced magnetic resonance imaging. J Am Soc Nephrol 17: 2359-2362, 2006 (Pubitemid 44300951)
4. Broome DR, Girguis MS, Baron PW, Cottrell AC, Kjellin I, Kirk GA: Gadodiamide-associated nephrogenic systemic fibrosis: Why radiologists should be concerned. AJR Am J Roentgenol 188: 586-592, 2007 (Pubitemid 46167763)
5. Khurana A, Runge VM, Narayanan M, Greene JF Jr, Nickel AE: Nephrogenic systemic fibrosis: A review of 6 cases temporally related to gadodiamide injection (Omniscan). Invest Radiol 42: 139-145, 2007 (Pubitemid 46104895)
6. Galan A, Cowper SE, Bucala R: Nephrogenic systemic fibrosis (nephrogenic fibrosing dermopathy). Curr Opin Rheumatol 18: 614-617, 2006 (Pubitemid 44607415)
7. Cowper SE. Nephrogenic Fibrosing Dermopathy [NFD/NSF Website]. 2001-2007. Available at: http://www.icnfdr.org. Accessed June 1, 2007
8. Thomsen HS, Morcos SK, Dawson P: Is there a causal relation between the administration of gadolinium based contrast media and the development of nephrogenic systemic fibrosis? Clin Radiol 61: 905-906, 2006
9. Thomsen HS: Nephrogenic systemic fibrosis: A serious late adverse reaction to gadodiamide. Eur Radiol 16: 2619-2621, 2006 (Pubitemid 44823915)
10. Food and Drug Administration: Public Health Advisory: Gadolinium-Containing Contrast Agents for Magnetic Resonance Imaging (MRI): Omniscan, OptiMARK, Magnevist, ProHance, and MultiHance, 2006. Available at: http://www.fda.gov/cder/drug/advisory/gadolinium-agents. htm. Accessed November 1, 2008
11. Food and Drug Administration: Public Health Advisory: Update on Magnetic Resonance Imaging (MRI) Contrast Agents Containing Gadolinium and Nephrogenic Fibrosing Dermopathy, 2006. Available at: http://www.fda.gov/cder/drug/advisory/ gadolinium-agents-20061222.htm. Accessed November 1, 2008
12. Perazella MA: Nephrogenic systemic fibrosis, gadolinium, and chronic kidney disease: Is there a link? Clin J Am Soc Nephrol 2: 200-202, 2007
13. Bellin MF: MR contrast agents, the old and the new. Eur J Radiol 60: 314-323, 2006
14. Lorusso V, Pascolo L, Fernetti C, Anelli PL, Uggeri F, Tiribelli C: Magnetic resonance contrast agents: From the bench to the patient. Curr Pharm Des 11: 4079-4098, 2005 (Pubitemid 41672479)
15. Runge VM: Safety of magnetic resonance contrast media. Top Magn Reson Imaging 12: 309-314, 2001 (Pubitemid 33031400)
16. Swan SK, Lambrecht LJ, Townsend R, Davies BE, McCloud S, Parker JR, Bensel K, LaFrance ND: Safety and pharmacokinetic profile of gadobenate dimeglumine in subjects with renal impairment. Invest Radiol 34: 443-455, 1999 (Pubitemid 29302836)
17. Wible JH, Troup CM, Hynes MR, Galen KP, MacDonald JR, Barco SJ, Wojdyla JK, Periasamy MP, Adams MD: Toxicological assessment of gadoversetamide injection (OptiMARK), a new contrast-enhancement agent for use in magnetic resonance imaging. Invest Radiol 36: 401-412, 2001
18. Niendorf HP, Alhassan A, Haustein J, Clauss W, Cornelius I: Safety and risk of gadolinium-DTPA: Extended clinical experience after more than 5,000,000 applications. Adv MRI Contrast 2: 12-19, 1993
19. Bellin MF, Deray G, Assogba U, Auberton E, Ghany F, Dion-Voirin E, Jacobs C, Grellet J: Gd-DOTA: Evaluation of its renal tolerance in patients with chronic renal failure. Magn Reson Imaging 10: 115-118, 1992
20. Arsenault TM, King BF, Marsh JW Jr, Goodman JA, Weaver AL, Wood CP, Ehman RL: Systemic gadolinium toxicity in patients with renal insufficiency and renal failure: Retrospective analysis of an initial experience. Mayo Clin Proc 71: 1150-1154, 1996 (Pubitemid 126765470)
21. Prince MR, Arnoldus C, Friscoli JK: Nephrotoxicity of high-dose gadolinium compared with iodinated contrast. J Magn Reson Imaging 6: 162-166, 1996 (Pubitemid 126702459)
22. Hammer FD, Goffette PP, Malaise J, Mathurin P: Gadolinium dimeglumine: An alternative contrast agent for digital subtraction angiography. Eur Radiol 9: 128-136, 1999
23. Spinosa DJ, Angle JF, Hagspiel KD, Aassar OS, Harthun NL, Tribble CG, Matsumoto AH: Lower extremity arteriography with use of iodinated contrast material or gadodiamide to supplement CO2 angiography in patients with renal insufficiency. J Vasc Interv Radiol 11: 35-43, 2000
24. Spinosa DJ, Matsumoto AH, Angle JF, Hagspiel KD, Cage D, Bissonette EA, Koenig KG, Ayers CR, McConnell K: Safety of CO2- and gadodiamide-enhanced angiography for the evaluation and percutaneous treatment of renal artery stenosis in patients with chronic renal insufficiency. AJR Am J Roentgenol 176: 1305-1311, 2001 (Pubitemid 32323280)
25. Sancak T, Bilgic S, Sanldilek U: Gadodiamide as an alternative contrast agent in intravenous digital subtraction angiography and interventional procedures of the upper extremity veins. Cardiovasc Intervent Radiol 25: 49-52, 2002 (Pubitemid 36918864)
26. Reiger J, Sitter T, Toepfer M, Linsenmaier U, Pfeofer KJ, Schiffl H: Gadolinium as an alternative contrast agent for diagnostic and interventional angiographic procedures in patients with impaired renal function. Nephrol Dial Transplant 17: 824-828, 2002 (Pubitemid 34521134)
27. Sam AD, Morasch MD, Collins J, Song G, Chen R, Pereles FS: Safety of gadolinium contrast angiography in patients with chronic renal insufficiency. J Vasc Surg 38: 313-318, 2003 (Pubitemid 41123255)
28. Erley CM, Bader BD, Berger ED: Gadolinium-based contrast media compared with iodinated media for digital subtraction angiography in azotemic patients. Nephrol Dial Transplant 19: 2526-2531, 2004
29. Ergun I, Keven K, Uruc I, Ekmekci Y, Canbakan B, Erden I, Karatan O: The safety of gadolinium in patients with stage 3 and 4 renal failure. Nephrol Dial Transplant 21: 697-700, 2006 (Pubitemid 43372917)
30. Briguori C, Colombo A, Airoldi F, Melzi G, Michev I, Carlino M, Montorfano M, Chieffo A, Bellanca R, Ricciardelli B: Gadolinium-based contrast agents and nephrotoxicity in patients undergoing coronary artery procedures. Catheter Cardiovasc Interv 67: 175-180, 2006 (Pubitemid 43235147)
31. Kane GC, Stanson AW, Kalnicka D, Rosenthal DW, Lee CU, Textor SC, Garovic VD: Comparison between gadolinium and iodine contrast for percutaneous intervention in atherosclerotic renal artery stenosis: Clinical outcomes. Nephrol Dial Transplant 23: 1233-1240, 2008 (Pubitemid 351767477)
32. Deo A, Fogel M, Cowper SE: Nephrogenic systemic fibrosis: A population study examining the relationship of disease development to gadolinium exposure. Clin J Am Soc Nephrol 2: 264-267, 2007
33. Nephrogenic fibrosing dermopathy associated with exposure to gadolinium-containing contrast agents: St. Louis, Missouri, 2002-2006. MMWR Morb Mortal Wkly Rep 56: 137-141, 2007
34. Sadowski EA, Bennett LK, Chan MR, Wentland AL, Garrett AL, Garrett RW, Djamali A: Nephrogenic systemic fibrosis: Risk factors and incidence estimation. Radiology 243: 148-157, 2007 (Pubitemid 46579705)
35. Marckmann P, Skov L, Rossen K, Heaf J, Thomsen HS: Case-control study of gadodiamide-related nephrogenic systemic fibrosis. Nephrol Dial Transplant 22: 3174-3178, 2007 (Pubitemid 350202540)
36. Collidge TA, Thomson PC, Mark PB, Traynor JP, Jardine AG, Morris ST, Simpson K, Roditi GH: Gadolinium-enhanced MR imaging and nephrogenic systemic fibrosis: Retrospective study of a renal replacement therapy cohort. Radiology 245: 168-175, 2007 (Pubitemid 47417800)
37. Othersen JB, Maize JC, Woolson RF, Budisavljevic MN: Nephrogenic systemic fibrosis after exposure to gadolinium in patients with renal failure. Nephrol Dial Transplant 22: 3179-3185, 2007 (Pubitemid 350202590)
38. High WA, Ayers RA, Chandler J, Zito G, Cowper SE: Gadolinium is detectable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56: 21-26, 2007 (Pubitemid 46017000)
39. Boyd AC, Zic JA, Abraham JL: Gadolinium deposition in nephrogenic fibrosing dermopathy. J Am Acad Dermatol 56: 27-30, 2007 (Pubitemid 44969309)
40. High WA, Eng M, Ayers RA, Cowper SE: Gadolinium is quantifiable within the tissue of patients with nephrogenic systemic fibrosis. J Am Acad Dermatol 56: 1-2, 2007
41. Schroeder JA, Weingart C, Coras B, Hausser I, Reinhold S, Mack M, Seybold V, Vogt T, Banas B, Hofstaedter F, Krämer BK: Ultrastructural evidence of dermal gadolinium deposits in a patient with nephrogenic systemic fibrosis and end-stage renal disease. Clin J Am Soc Nephrol 3: 968-975, 2008
42. Broome DR: Nephrogenic systemic fibrosis associated with gadolinium based contrast agents: A summary of the medical literature reporting. Eur J Radiol 66: 230-234, 2008
43. Wertman R, Altun E, Martin DR, Mitchell DG, Leyendecker JR, O'Malley RB, Parsons DJ, Fuller ER 3rd, Semelka RC: Risk of nephrogenic systemic fibrosis: Evaluation of gadolinium chelate contrast agents at four American universities. Radiology 248: 799-806, 2008
44. Reilly RF: Risk for nephrogenic systemic fibrosis with gadoteridol (ProHance) in patients who are on long-term hemodialysis. Clin J Am Soc Nephrol 3: 747-751, 2008
45. Sieber MA, Lengsfeld P, Frenzel T, Golfier S, Schmitt-Willich H, Siegmund F, Walter J, Weinmann HJ, Pietsch H: Preclinical investigation to compare different gadolinium-based contrast agents regarding their propensity to release gadolinium in vivo and to trigger nephrogenic systemic fibrosis-like lesions. Eur Radiol 18: 2164-2173, 2008
46. Chapman A, Grantham JJ, Guay-Woodford LM, Braun W, Rahbari-Oskovi F, Kelleher C, Schrier RW, Perrone R, Steinman T, Miskalin D, Meyers C, Bost J, Miller P, Bae KT: Absence of NSF following gadolinium exposure in ADPKD individuals with stable CKD [Abstract]. J Am Soc Nephrol 18: 759A, 2007
47. Rydahl C, Thomsen HS, Marckmann P: High prevalence of nephrogenic systemic fibrosis in chronic renal failure patients exposed to gadodiamide, a gadolinium-containing magnetic resonance contrast agent. Invest Radiol 43: 141-144, 2008